98%
921
2 minutes
20
Background: The new heart allocation policy places veno-arterial extracorporeal membrane oxygenation (VA-ECMO)-supported heart transplant (HT) candidates at the highest priority status. Despite increasing evidence supporting left ventricular (LV) unloading during VA-ECMO, the effect of LV unloading on transplant outcomes following bridging to HT with VA-ECMO remains unknown.
Methods And Results: From October 18, 2018 to March 21, 2023, 624 patients on VA-ECMO at the time of HT were identified in the United Network for Organ Sharing database and were divided into 2 groups: VA-ECMO alone (N=384) versus VA-ECMO with LV unloading (N=240). Subanalysis was performed in the LV unloading group: Impella (N=106) versus intra-aortic balloon pump (N=134). Recipient age was younger in the VA-ECMO alone group (48 versus 53 years, =0.018), as was donor age (VA-ECMO alone, 29 years versus LV unloading, 32 years, =0.041). One-year survival was comparable between groups (VA-ECMO alone, 88.0±1.8% versus LV unloading, 90.4±2.1%; =0.92). Multivariable Cox hazard model showed LV unloading was not associated with posttransplant mortality after HT (hazard ratio, 0.92; =0.70). Different LV unloading methods had similar 1-year survival (intra-aortic balloon pump, 89.2±3.0% versus Impella, 92.4±2.8%; =0.65). Posttransplant survival was comparable between different Impella versions (Impella 2.5, versus Impella CP, versus Impella 5.0, versus Impella 5.5).
Conclusions: Under the current allocation policy, LV unloading did not impact waitlist outcome and posttransplant survival in patients bridged to HT with VA-ECMO, nor did mode of LV unloading. This highlights the importance of a tailored approach in HT candidates on VA-ECMO, where routine LV unloading may not be universally necessary.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179799 | PMC |
http://dx.doi.org/10.1161/JAHA.123.033590 | DOI Listing |
J Clin Med
August 2025
Department of Critical Care Medicine, Christian Medical College, Vellore 632004, India.
: High-risk percutaneous coronary interventions (HR-PCIs) often require mechanical circulatory support (MCS) to maintain hemodynamic stability. Intra-aortic balloon pump (IABP) and percutaneous left ventricular assist device (PLVAD) are two commonly used MCS devices that differ in their mechanisms. We aimed to evaluate and compare the clinical outcomes associated with IABP and PLVAD use in HR-PCIs without cardiogenic shock.
View Article and Find Full Text PDFASAIO J
August 2025
Division of Cardiology, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi.
Anecdotally, over the past 2 years, many transplant centers in the United States have shifted toward using Impella 5.5 instead of intra-aortic balloon pumps (IABP) for less sick patients. The aim of our study is to determine if Impella 5.
View Article and Find Full Text PDFEur Heart J Qual Care Clin Outcomes
July 2025
University College London, London, UK.
Aim: Cardiogenic shock (CS) is a common sequitur in acute myocardial infarction (AMI), with significant associated mortality. Mechanical circulatory support (MCS) devices have been used in the management of AMI complicated by CS (AMICS). The relative safety and efficacy of these devices in this context is not yet fully established.
View Article and Find Full Text PDFReports (MDPI)
April 2025
Cardiovascular Medicine, Premier Heart Institute, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA.
Takotsubo cardiomyopathy (TCM), an acute stress-induced left ventricular dysfunction, stems from catecholaminergic surges leading to transient myocyte stunning, calcium overload, and microvascular dysregulation. Although most cases resolve spontaneously, roughly 10% deteriorate into fulminant cardiogenic shock, warranting mechanical circulatory support (MCS). Impella provides direct transvalvular LV unloading but carries elevated risks of hemolysis, vascular compromise, and thrombogenicity.
View Article and Find Full Text PDFJTCVS Open
June 2025
Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY.
Objective: The US Food and Drug Administration approved the use of Impella 5.5 (Abiomed) for mechanical circulatory support for up to 14 days, but many patients require longer duration of support. This study sought to compare outcomes of standard versus prolonged Impella 5.
View Article and Find Full Text PDF